Cataract Therapeutics

Latest News

Melt Pharmaceuticals reports positive Phase 3 topline efficacy results for MELT-300
Melt Pharmaceuticals reports positive Phase 3 topline efficacy results for MELT-300

November 20th 2024

Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The results support a regulatory submission, with potential to revolutionize sedation practices in various medical specialties.

Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007
Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007

November 6th 2024

AAO 2024: Livionex reports positive end-of-phase 2 meeting with FDA on the development of C-KAD eye drop to treat early to moderate cataracts
AAO 2024: Livionex reports positive end-of-phase 2 meeting with FDA on the development of C-KAD eye drop to treat early to moderate cataracts

October 18th 2024

Melt Pharmaceuticals doses final patient in phase 3 trial of MELT-300
Melt Pharmaceuticals doses final patient in phase 3 trial of MELT-300

October 11th 2024

Efficacy of novel eye drop to reverse cataracts after phase 1/2 study
Efficacy of novel eye drop to reverse cataracts after phase 1/2 study

August 25th 2024

Video Interviews
Podcasts
EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
Latest CME Events & Activities

(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action

View More

Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)

View More

Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)

View More

(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action

View More

Advancing Treatment in Neovascular Retinal Disease with Novel Therapies: Insights and Strategies from Latest Real-World and Clinical Data

View More

Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME

View More

(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium

View More

(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon

View More

(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon

View More

(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment

View More

(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment

View More

(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape

View More

(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape

View More

Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)

View More

Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)

View More

SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management

View More

EnVision Summit

February 14-17, 2025

Register Now!

Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

March 16, 2025

Register Now!

Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care

View More

Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)

View More

Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)

View More

Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)

View More

Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)

View More

Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)

View More

Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)

View More

Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)

View More

Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)

View More

Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)

View More

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)

View More

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)

View More

More News

© 2024 MJH Life Sciences

All rights reserved.